Skip to content
Brand AI

Alesta Therapeutics

Recent events

Recent events tied to this brand in public sources.

Back to profile1 entries

  1. 2026

    BioMarin announces acquisition of Alesta Therapeutics for $275m upfront

    BioMarin Pharmaceutical announced it will acquire Alesta Therapeutics for $275 million upfront plus up to $215 million in development and regulatory milestones, bringing the clinical-stage oral hypophosphatasia candidate ALE1 into its pipeline. The deal was approved by both boards, Alesta will spin out all non-ALE1 assets to a new entity before closing, and the transaction is expected to close this quarter subject to customary closing conditions.

    Source